Mr. James Howard-Tripp reports

STAGEZERO LIFE SCIENCES ADDS BREASTSENTRY AND PROSTATE HEALTH INDEX TO LICENSING AND SERVICES AGREEMENT WITH ONCORE PHARMA

Stagezero Life Sciences Ltd. has expanded its multiyear licensing agreement with Oncore Pharma Inc.

According to the company, Oncore Pharma, in addition to commercializing ColonSentry under the exclusive five-year licensing agreement, will now add BreastSentry and the Prostate Health Index to its offering. The initial agreement with Oncore Pharma for ColonSentry has the aim to deploy a total of 1.75 million tests over the next five years. The addition of BreastSentry and the Prostate Health Index will add significantly to this.

Under the terms of the agreement, Oncore Pharma and its partners will bear all costs of marketing and distributing the tests, as well as collection of the test samples and shipping to Stagezero's laboratory in Richmond, Va. Stagezero will receive a fixed fee for processing and reporting the tests. Additionally, Stagezero has received one million common shares of Oncore Pharma and will receive a special royalty payment equal to 10 per cent of Oncore's yearly profits.

"We created Oncore Pharma to focus specifically on research, development and commercialization of oncology products, and ColonSentry is exactly the type of diagnostic test the market needs and our customers demand," commented Martin Verronneau, president and chief executive officer of Oncore Pharma. "With the recent publication in breast cancer following the NCRI Cancer Conference of Glasgow, we have been asked to expand our offering with BreastSentry and the Prostate Health Index to allow for screening of multiple cancers."

"There is significant interest in being able to screen easily and routinely for multiple cancers, and our tests meet this need," commented James Howard-Tripp, chairman and chief executive officer of Stagezero Life Sciences. "Our combined ability to engage with patients, particularly in the early detection of cancers like colorectal, breast and prostate, are very topical in Europe and in demand. Oncore Pharma's experience in bringing products to market, coupled with their scientific knowledge, provides our company with a great advantage. BodyCheck NL, Oncore Pharma's partner in the Benelux countries, has indicated they will initiate testing during the first quarter of next year (2020)."

About Stagezero Life Sciences Ltd.

Stagezero Life Sciences is dedicated to the early detection of cancer and multiple disease states through whole blood.